NCT06163053已完成不适用
A French Non-interventional Prospective Multicenter Study Evaluating Quality of Care Perception of Cancer Patients Treated by Immunotherapy at Home - SATISFACT-HOME
Bristol-Myers Squibb3 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2023年8月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 3
- 主要终点
- Change in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy
研究概览
简要总结
The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years old
- •Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
- •Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
- •Participants who provide oral informed consent to participate in the study
排除标准
- •Participants who have expressed an opposition to their data collection
- •Participants under guardianship
- •Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
研究组 & 干预措施
Participants receiving immunotherapy at home
干预措施: Immunotherapy (Drug)
结局指标
主要结局
Change in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy
时间窗: Participants follow up approximately 24 weeks after transition to treatment at home
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
PRostate Olaparib Real World Evidence StudyMetastatic Castration-resistant Prostate CancerNCT06031805AstraZeneca300
已完成
不适用
e-BioMatrix 6 Month DAPT FranceCoronary Artery StenosesIschemiaNSTEMI - Non-ST Segment Elevation MIStable AnginaSTEMINCT03461484Biosensors Europe SA2,098
已完成
不适用
French National Registry of Children Born Small for Gestational Age Treated With SomatropinGrowth DisorderSmall for Gestational AgeNCT01578135Novo Nordisk A/S291
已完成
不适用
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerRenal Cell CancerAdenocarcinoma Of KidneyAdenocarcinoma, Renal CellKidney CancerCancer of the KidneyRenal Cell CarcinomaNCT03455452Bristol-Myers Squibb623
进行中（未招募）
不适用
A French Non Interventional Multicentric Cohort Study in Patients With Colorectal DysplasiaHyperplasiaDysplasiaNCT01816438Hôpital Edouard Herriot300